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investigation is required to determine the efﬁcacy of HCQ in other hand
OA phenotypes.
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THE EFFECT OF WALKING EXERCISE REGIMENS ON JOINT
BIOMECHANICS AND SERUM BIOMARKER PROFILE IN PATIENTS
WITH KNEE OSTEOARTHRITIS
P. Jayabalan y, J. Gustafson z, S. Piva z, G. Sowa y, S. Farrokhi z. yDept. of
Physical Med. & Rehabilitation, Univ. of Pittsburgh Med. Ctr., Pittsburgh,
PA, United States; zDept. of Physical Therapy, Univ. of Pittsburgh,
Pittsburgh, PA, United States
Purpose: Although walking exercise is commonly prescribed to
patients with knee osteoarthritis (OA), there is limited evidence
regarding the safe mode and volume of walking exercise beyond which
a patient may be potentiating further joint damage leading to reduced
clinical beneﬁts. The present study is the ﬁrst that aims to determine
the speciﬁc features of a walking exercise program beyond which
accelerated rates of joint damage are expected using both bio-
mechanical and biochemical outcome measures. Objective 1: Deter-
mine the inﬂuence of increasing walking volume as a single continuous
session versus multiple intermittent shorter sessions on knee joint
biomechanics as assessed by the change in the knee contact force (KCF)
proﬁle. Objective 2: Investigate the effect of continuous versus inter-
mittent walking regimen on serum concentration of a biomarker that
has been associated with cartilage turnover (cartilage oligomatrix
protein, COMP).
Methods: Twenty-eight subjects aged >50 with unilateral sympto-
matic knee OA who met the American College of Rheumatology
clinical criteria and a Kellgren-Lawrence radiographic OA grading of
>2 were recruited. All subjects completed two walking exercise ses-
sions separated by at least 72 hours: 1) a single session of 45 minutes
of continuous walking, and 2) three separate 15-minute bouts of
walking with a 1-hour rest period between each bout, for a total of 45
minutes of walking exercise. For both walking sessions, biomechanical
data consisting of passive marker trajectories and ground reaction
force data along with 5-ml blood samples were collected at baseline
and after every 15 minutes of cumulative walking exercise. Passive
marker trajectories and ground reaction force data were used to create
subject speciﬁc, muscle driven, gait simulations using Opensim to
estimate the ﬁrst and second peaks in the KCF while walking on a
treadmill. Additionally, serum concentration of COMP was quantiﬁed
using ELISA. To determine whether KCFs or Serum COMP concen-
trations varied between continuous and intermittent walking con-
ditions, a 2x4 (condition x walking time) factorial analysis of variance
(ANOVA) with repeated measures was performed for each variable of
interest.
Results: A signiﬁcant walking time effect was observed for the ﬁrst peak
in KCF (F3,81¼ 5.52, P ¼ 0.002) but there was no condition effect or a
condition x walking time interaction. When averaged across the two
walking conditions, post-hoc analysis revealed a signiﬁcant increase in
the ﬁrst peak of KCF equivalent to 25% of body weight after 30 minutes
(P¼0.004) and 45 minutes of cumulative walking (P¼0.009). No con-
dition effect, walking time effect, or condition x walking time inter-
action was observed for the second peak in KCF. A signiﬁcant condition
x walking time interaction (F3,81¼3.50, P¼ 0.02) was also observed for
the changes in COMP concentration, but there were no signiﬁcant
condition effect or walking time effect. Continuous walking was asso-
ciated with a signiﬁcant cumulative increase in COMP concentration
from baseline to 45 minutes (23% increase, P < 0.05), whereas, COMP
concentrations dropped to baseline levels after 30 minutes of inter-
mittent walking with rest breaks.
Conclusions: Cumulative increases in walking exercise volume of
greater than 30 minutes (irrespective of walking regimen) were asso-
ciated with an increase in the ﬁrst peak in KCF equivalent to 25% of body
weight, suggesting a signiﬁcant increase in articular cartilage loading
proﬁles that may be undesirable. The continuous walking regimen
appeared to potentiate an increase in serum COMP concentration at 45
minutes, while an intermittent walking regimen that involved rest
breaks did not. Together our preliminary ﬁndings suggest that pre-
scription of walking exercise of greater than 30 minutes may lead to
undesirable joint loading conditions, while addition of rest breaks may
attenuate the potential negative effects of longer bouts of walking
exercise on cartilage health.39
ADDRESSING CONTROVERSIES AROUND INTRA-ARTICULAR
INJECTIONS WITH HYALURONIC ACID IN THE TREATMENT OF
OSTEOARTHRITIS: META-REGRESSION ANALYSES OF RANDOMIZED
TRIALS
M. Johansen y,z, H. Bahrt y,z, R. Altman x, E. Bartels y, C. Juhl z,k,
H. Bliddal y, H. Lund y,¶, R. Christensen y. y The Parker Inst., Dept. of
Rheumatology. Bispebjerg and Frederiksberg Hosp., Copenhagen,
Denmark; z SEARCH, Inst. of Sports Sci. and Clinical Biomechanics,
Faculty of Hlth. Sci., Univ. of Southern Denmark, Odense, Denmark;
xDavid Geffen Sch. of Med., Univ. of California, Los Angeles, CA, United
States; kDept. of Physiotherapy, Copenhagen Univ. Hosp., Gentofte,
Hellerup, Denmark; ¶Høgskolen i Bergen, Bergen, Norway
Purpose: Intra-Articular injections (IA) with hyaluronic acid (HA) are
used for treating symptomatic osteoarthritis (OA), despite divergent
opinions concerning its effectiveness. The aim of this study was to
explore and identify factors from randomized trials (RCTs), which
explain controversies around the potential efﬁcacy of IA HA compared
to IA sham, IA control, or non-intervention control therapies in patients
with symptomatic OA of the knee, hip and other joints.
Methods: A systematic review and stratiﬁed meta-analysis of available
RCTs was conducted. Methods of the analysis and inclusion criteria
were speciﬁed in advance and registered in the International Pro-
spective Register of Systematic Reviews, PROSPERO registration no.
CRD42014007284. MEDLINE, EMBASE, Cochrane Central Register of
Controlled trials (CENTRAL), Web of science and other resources were
searched for trials in any language. The outcome “pain” was assessed
according to a pre-speciﬁed hierarchy of potentially available outcomes.
Reviewers used duplicate abstractions and independently assessed risk
of bias using the risk of bias tool recommended by Cochrane Collabo-
ration. Hedges’s standardized mean difference (SMD [95%CI]) served as
effect size. REstricted Maximum Likelihood (REML) mixed-effects
models were used to combine study results calculating I-squared and
Tau-squared estimates using STATA. To empirically quantify reasons for
the apparent heterogeneity across studies, a number of stratiﬁed
analyses of the primary outcome were performed according to the trial
characteristics.
Results: Ninety-nine trials, including 115 comparisons (14,804
patients), met the inclusion criteria: Of these, 85 comparisons (11,216
patients) had adequate data available for enabling inclusion in the
meta-analysis. Compared with control, HA reduced pain with an effect
size of -0.39 [-0.47 to -0.41; P<0.001]. There was a high level of
inconsistency (I2¼73%). Adjusting for selective outcome reporting in 30
of the comparisons by imputing data from “null ﬁndings” for the studies
that did not report on pain reduced the combined estimate to -0.30
[-0.37 to -0.23; P<0.001]. Three important variables explaining the high
heterogeneity were overall risk of bias, blinding of personnel and trial
size. Overall risk of bias reduced the heterogeneity (according to Tau-
squared) by 26 %, showing an effect size for low risk of bias trials of
-0.00 [-0.13 to 0.12] compared to -0.35 [-0.43 to -0.27] and -0.81 [-1.19
to -0.44] for high and unclear risk of bias, respectively. Furthermore,
blinding of personnel and trial size reduced the heterogeneity by 26%
and 25% respectively (interaction P<0.001).
Conclusions: Based on available trials, IA HA showed statistically sig-
niﬁcant clinical effect. Small-study bias and the risk of selective out-
come reporting, suggest a lower effect size corresponding to a small,
although statistically signiﬁcant, effect. Stratiﬁed analyses showed
three important variables explaining heterogeneity; Overall Risk of Bias,
blinding of personnel and trial size. Trials with low risk of bias did not
seem to be associated with effect.
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DOES PATELLO-FEMORAL BRACE THERAPY REDUCE SYNOVITIS
ASSESSED BY DYNAMIC CONTRAST ENHANCED MRI?
V. Swaminathan y, M.J. Parkes y, R. Hodgson y, M.J. Callaghan y,
D.T. Felson z, T.W. O'Neill y. y The Univ. of Manchester, Manchester, United
Kingdom; zBoston Univ., Boston, MA, United States
Purpose: Osteoarthritis (OA) is associated with inﬂammatory changes
within an affected joint including synovitis. We previously demon-
strated that a patellar brace both reduced pain and decreased MRI
bone marrow lesions in patellofemoral joint (PFJ) OA. While static
synovial volume was not affected by this brace, RA studies and our
ﬁndings in a steroid trial (OARSI, 2014) suggest that changes in the
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81A48enhancement of synovium during dynamic contrast enhanced mag-
netic resonance imaging (DCE-MRI) correlate more strongly with
reduction in pain severity than changes in static synovial volume. The
aim of this analysis was to determine the impact of a PFJ brace on
synovitis as assessed by change in synovial enhancement using DCE-
MRI.
Methods: One hundred and twenty six people aged between 40 and 70
years with PFJ OA were recruited into a randomised clinical trial of a
patellar brace. Participants were randomised to an intervention
(wearing brace) and a control group (no brace) for six weeks. Subjects
were assessed at baseline and at 6 weeks for pain using the KOOS
questionnaire and also a visual analogue score (VAS) scored from 0-
100mm for a nominated physical activity (VASNA). They also had DCE-
MRI of the symptomatic knee performed at baseline and at 6 weeks.
Dynamic synovial parameters were calculated based on the enhance-
ment of synovium with contrast including; maximum rate of
enhancement (max-grad), late relative enhancement (late-rel), max-
imum enhancement (max) and volume transfer coefﬁcient (ktrans). We
used a paired t-test to look at within group change in both pain and
DCE-MRI parameters before and after intervention and an unpaired t-
test to look at the between group difference in the change in these
parameters.
Results: Subjects’ mean age was 55.5 years (SD ¼ 7.5) and 72 (57.1%)
were female. Pain improved signiﬁcantly within the intervention group
though not the control group. There was a signiﬁcant between group
difference in the change in both KOOS and VASNA, see Table. Within
controls there was a reduction in all of the dynamic parameters
between baseline and follow up. This was signiﬁcant for volume
transfer coefﬁcient (within group difference in ktrans ¼ -0.003) and
also maximum rate of enhancement (within group difference in max-
grad ¼ -0.198). Within the intervention group there was a small
increase (worsening) in all of the dynamic MRI parameters between
baseline and 6 weeks follow up though none of these differences was
statistically signiﬁcant. There was a signiﬁcant difference in the change
in maximum rate of enhancement (max) between the intervention and
control groups.
Conclusions: Patellofemoral joint brace therapy for patients with
symptomatic patellofemoral knee OA does not reduce synovitis as
suggested by change in synovial enhancement using DCE-MRI. Pain
reduction following brace therapy can not therefore be explained by
change in synovitis.Table 1
Changes in Dynamic MRI Factors Following Brace Intervention
Variables No brace group (N¼63) Brace group (N¼63)
Within group mean diff (95% CI) p Within group mean diff (95% CI) p Between-group mean diff (95% CI) p
ktrans 0.003 (0.006 to 0.000) 0.05 0.001 (0.003 to 0.005) 0.63 0.002 (0.009 to 0.001) 0.11
max_grad 0.198 (0.345 to 0.050) 0.01 0.171 (0.013 to 0.356) 0.07 0.116 (0.599 to 0.139) <0.01
late_rel 0.102 (0.280 to 0.076) 0.25 0.010 (0.175 to 0.195) 0.91 0.128 (0.367 to 0.142) 0.38
max 0.161 (0.357 to 0.036) 0.11 0.045 (0.166 to 0.256) 0.67 0.143 (0.491 to 0.079) 0.15
Pain on nominated activity VAS 0.13 (0.64 to 0.38) 0.61 1.82 (2.39 to 1.24) <0.01 0.38 (0.93 to 2.44) <0.01
KOOS Pain Subscale Score 1.71 (1.66 to 5.08) 0.31 8.78 (4.36 to 13.20) <0.01 2.75 (12.51 to 1.61) 0.0141
PERCEIVED BARRIERS IN CARE FOR OSTEOARTHRITIS
E.M. Badley y, C. Nagamuthu y, L. Moore z, M.A. Gignac x. yUniv. Hlth.
Network, Toronto, ON, Canada; z The Arthritis Society, Toronto, ON,
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Purpose:While osteoarthritis (OA) is the most frequent type of arthritis
in the population, relatively little attention has been paid to patients’
perceptions of the impact of their disease and the barriers they face in
receiving care. This study examined current treatments and barriers to
treatment, as well as perceptions around decision making and the
preferences of patients for physician input into their OA treatment.
Methods: A poll of people with arthritis was commissioned to gather
data on patient perceptions with the purpose of improving the infor-
mation presented on The Arthritis Society of Canada website.
Respondents were asked for their disease diagnosis; impact of arthritis
(e.g., pain, fatigue, disability with activities and social roles); barriers
and challenges in getting care; and preferences for physicianinvolvement in care decisions. Most questions were on a 1 to 5 scale
ranging from 1 ¼ no impact/importance to 5 ¼ extreme impact/
importance. Scores are reported as means or percentages unless oth-
erwise stated.
Results: Of the 1715 respondents, 922 (53.8%) reported osteoarthritis
(OA) and 588 (34.3%) reported OA as their sole type of arthritis.We focus
on those with OA as a sole diagnosis. Eighty two percent were female;
57% were aged 5 years. The mean pain intensity was 5.9 on a 1-10 scale
with 70% reporting pain at least once aweek. Themean number of joints
affectedwas 3.8 (out of 13). However, 44% of participants reported taking
no medications for their OA. The impact of OA on daily activities was
moderatewithmean scores in the range of 2.2-3.0 out of 5 for family and
social-related activities. The greatest impact of OAwas for exercise (3.3)
and intimate relations (4.4). Respondents reported controlling pain,
mobility and stiffness, loss of strength, fatigue, low energy and difﬁculty
sleeping as being of high importance (range ofmean scores 4.1-4.4) with
no differences by age. Overall 75% of respondents reported at least one
challenge in getting treatment with the top 3 challenges being a lack of
affordable treatment (30.1%), long wait times for appointments (28.3%),
and a perceived absence of beneﬁcial treatment (e.g., ”don’t think any-
thing can be done”) (26.3%). Costs for treatments like physiotherapy and
over-the-counter medication were noted in particular. Respondents
rated highly the importance of physicians considering their input when
making decisions related to prescription medication (mean ¼ 4.4) and
treatments such as surgery or physiotherapy (mean ¼ 4.4). However
they expressed lower perceived importance for seeking physician input
before deciding on treatments such as diet and exercise (mean¼3.7) and
over-the counter-medications (mean ¼ 3.8).
Conclusions: Despite pain, a moderate impact on valued roles and
activities, and a high importance of controlling a range of symptoms,
two-ﬁfths of people with OAwere not taking any medications, which is
in line with ﬁndings from other studies. Of concern was that most
respondents reported challenges and hardships with getting treatment,
including costs not covered by the health care system and a perception
that little was available to them in the way of efﬁcacious care for OA.
Moreover, clinician input was not always seen as important in man-
agement of all aspects of OA. There is a clear need for better information
for patients on what can be done to control their illness and for inter-
ventions to minimize barriers in accessing appropriate treatments.
Additional research on decision-making preferences related to OA
treatment would be beneﬁcial in addressing a patient-centred approach
to OA management.42
FOLATE RECEPTOR POSITIVE MACROPHAGES IN OSTEOARTHRITIS
AND EFFECTS OF TRIAMCINOLONE
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Purpose: Folate-based radiotracers have been used in patients with
cancer and inﬂammatory diseases to visualize folate receptor express-
ing cells using PET or SPECT techniques. Activated macrophages express
folate receptor beta (FR-b) and this allows speciﬁc imaging of these cells
in-vivo. From previous work using SPECT imaging to visualize folate
receptor expressingmacrophages in both animal models and in patients
with OA we know that macrophages are present in OA affected joints.
However, it remains unclear what role these macrophages play in the
